Cargando…

Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease

Limited data are available regarding optimal treatment for refractory Mycobacterium avium complex-pulmonary disease (MAC-PD). We evaluated outcomes of inhaled amikacin (AMK) with clofazimine (CFZ) regimens as an add-on salvage therapy for refractory MAC-PD. We retrospectively analyzed 52 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Bo-Guen, Kim, Hojoong, Kwon, O. Jung, Huh, Hee Jae, Lee, Nam Yong, Baek, Sun-Young, Sohn, Insuk, Jhun, Byung Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565500/ https://www.ncbi.nlm.nih.gov/pubmed/32937940 http://dx.doi.org/10.3390/jcm9092968

Ejemplares similares

Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
por: Zweijpfenning, Sanne M.H., et al.
Publicado: (2021)

Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity
por: Kim, Bo-Guen, et al.
Publicado: (2022)

In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease
por: Kim, Dae Hun, et al.
Publicado: (2021)

Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates
por: Kim, Su-Young, et al.
Publicado: (2021)

A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
por: Lee, Ju Mi, et al.
Publicado: (2021)

Role of Clofazimine in Treatment of Mycobacterium avium Complex
por: Nasiri, Mohammad Javad, et al.
Publicado: (2021)

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
por: Marras, Theodore K., et al.
Publicado: (2022)

Novel Administration of Clofazimine for the Treatment of Mycobacterium avium Infection
por: Valinetz, Ethan, et al.
Publicado: (2020)

Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion
por: Brown-Elliott, Barbara A, et al.
Publicado: (2018)

Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings
por: Morita, Atsuho, et al.
Publicado: (2022)

Spontaneous Cultural Conversion Rate of Mycobacterium avium Complex Pulmonary Disease Based on BACES Severity
por: Kim, Bo-Guen, et al.
Publicado: (2023)

Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease
por: Zo, Sungmin, et al.
Publicado: (2022)

Amikacin liposome and Mycobacterium avium complex: A systematic review
por: Zangiabadian, Moein, et al.
Publicado: (2022)

Successful treatment of refractory cutaneous infection caused by Mycobacterium marinum with a combined regimen containing amikacin
por: Huang, Yingxue, et al.
Publicado: (2012)

Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease
por: Asakura, Takanori, et al.
Publicado: (2019)

Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report
por: Hashimoto, Kazuki, et al.
Publicado: (2023)

Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series
por: Davis, Kala K, et al.
Publicado: (2007)

Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use
por: Kim, Seong Min, et al.
Publicado: (2023)

Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Preliminary Evaluation of a Sitafloxacin-Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium avium Complex Disease
por: Fujita, Kohei, et al.
Publicado: (2016)

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients
por: Caimmi, Davide, et al.
Publicado: (2018)

Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection
por: Lee, Ju Mi, et al.
Publicado: (2023)

Clofazimine for Treatment of Mycobacterium abscessus Infections in Children
por: Adler-Shohet, Felice C, et al.
Publicado: (2017)

Laryngitis after inhalation of liposomal amikacin
por: Morita, Atsuho, et al.
Publicado: (2022)

Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis
por: Zhang, Lei, et al.
Publicado: (2023)

Liposomal Amikacin Inhalation Suspension-induced Pneumonitis
por: Kidogawa, Moe, et al.
Publicado: (2022)

Characteristics of Circulating CD4(+) T Cell Subsets in Patients with Mycobacterium avium Complex Pulmonary Disease
por: Han, Sun Ae, et al.
Publicado: (2020)

The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
por: Khan, Omer, et al.
Publicado: (2020)

Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates
por: Park, Sanghee, et al.
Publicado: (2022)

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience
por: Chiron, Raphael, et al.
Publicado: (2022)

In Vitro Activity of Benzimidazole (SPR719) Against Clinical Isolates of Nontuberculous Mycobacteria With and Without Clarithromycin or Amikacin Resistance
por: Kim, Dae Hun, et al.
Publicado: (2024)

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
por: Henriette Zweijpfenning, Sanne Maria, et al.
Publicado: (2022)

The lung microbiota in nontuberculous mycobacterial pulmonary disease
por: Kim, Bo-Guen, et al.
Publicado: (2023)

Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
por: Zhang, Jimin, et al.
Publicado: (2018)

Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
por: Sonnenkalb, Lindsay, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ljs1kqi03dede0dqktk98he4eo